Astrazeneca

AstraZeneca starts Phase III program for asthma drug tralokinumab – Pharmaceutical Business Review

AstraZeneca starts Phase III program for asthma drug tralokinumabPharmaceutical Business ReviewAstraZeneca has started the Phase III program for an investigational human monoclonal antibody tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company's global biologics…